drugset
drugset / Trial / NCT05895812

A Study in Subjects With Renal Impairment Compared to Subjects With Normal Renal Function

NCT05895812 ↗

Phase 1 Completed 24 enrolled Shanghai Vinnerna Biosciences Co., Ltd. Sponsor GmbH · collab
Non-randomizedParallel-groupOpen-labelOther

Summary

The purpose of this study is to evaluate the pharmacokinetics and safety of a single dose of JT001 in adult subjects with mild and moderate renal impairment compared to healthy mean-matched subjects.The results of this study will guide the clinical recommendation regarding whether or not a dose adjustment may be needed when treating patients with renal impairment.

Timeline

Start
2023-05-08
Primary completion
2023-08-25
Completion
2023-08-28

Drugs

EvaluationDrugModalityDoseRoute
Subject REMIDEVIR Small molecule 0.3 g Oral

Indications

No indication recorded.